Cargando…
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection
BACKGROUND: The duration of viral shedding is central to the guidance of decisions about isolation precautions and antiviral treatment. However, studies regarding the risk factors associated with prolonged shedding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the impact of...
Autores principales: | Yan, Dan, Liu, Xiao-Yan, Zhu, Ya-nan, Huang, Li, Dan, Bi-tang, Zhang, Guo-jun, Gao, Yong-hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241115/ https://www.ncbi.nlm.nih.gov/pubmed/32430428 http://dx.doi.org/10.1183/13993003.00799-2020 |
Ejemplares similares
-
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
por: Cheng, Chien-Yu, et al.
Publicado: (2020) -
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
por: Lecronier, Marie, et al.
Publicado: (2020) -
Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2–infected patient
por: Stalder, Gregoire, et al.
Publicado: (2020) -
Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir()
por: Gimeno Castillo, Javier, et al.
Publicado: (2021) -
Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)